The results reported here show that controlled delivery of supra-physiological doses of recombinant TG-VEGF protein could be effective to overcome the diabetes-induced impairment of spontaneous reparative angiogenesis and, in particular, the combination with TG-PDGF-BB can limit undesired effects of the high VEGF dose, such as excessive vascular enlargement. The gene discussed is VEGFA; the disease is diabetes mellitus.